Personalized microbiome-driven effects of non-nutritive sweeteners on human glucose toleranceOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study examined whether non-nutritive sweeteners (NNS), long presumed to be metabolically inert, actually alter the human microbiome and glucose tolerance. The researchers ran a randomized-controlled trial testing four NNS, saccharin, sucralose, aspartame, and stevia, given as sachets for two weeks at doses below the acceptable daily intake. They compared outcomes against control groups receiving vehicle glucose or no supplement, and measured effects on stool and oral microbiome composition, plasma metabolome, and glycemic responses. They also used gnotobiotic mice conventionalized with human donor microbiomes to test whether the microbiome could causally transmit these effects.
Who was studied?
The human arm of the study enrolled 120 healthy adults, randomized to receive saccharin, sucralose, aspartame, stevia, vehicle glucose, or no supplement for two weeks. In parallel, the researchers used gnotobiotic mice conventionalized with microbiomes drawn from multiple top and bottom glycemic responders within each of the four NNS-supplemented human groups. This combination allowed comparison of directly treated humans with mice whose only exposure to NNS effects came through transplanted human microbiomes.
What were the most important findings?
Each of the four NNS distinctly altered the stool and oral microbiome and plasma metabolome as a group, even at doses below the acceptable daily intake. Saccharin and sucralose specifically caused significant impairment of glycemic responses in the human participants. When gnotobiotic mice were conventionalized with microbiomes from top and bottom human responders, their glycemic responses largely mirrored those of their respective human donors. Distinct microbial signals, exemplified in the sucralose group, preempted these glycemic outcomes, indicating the microbiome was mechanistically involved rather than merely correlated.
What are the greatest implications of this study?
The findings challenge the assumption that non-nutritive sweeteners are metabolically inert, showing instead that they can alter the microbiome and glycemic control even at doses within currently accepted safety limits. Because effects were person-specific and transmissible via microbiome transplantation, individual microbiome composition may determine who experiences adverse glycemic responses to a given sweetener. The authors conclude that these person-specific, microbiome-dependent effects warrant further assessment of their clinical implications for human health.